Limitations and Options for Targeted Therapy of Anaplastic Thyroid Cancer: a Novel genome-based Approach. Supplementary

In order to find new therapeutic
options in anaplastic thyroid cancer, first all FDA-approved drugs for any
cancer therapy were identified by searching the databases of National Cancer
Institute and MyCancerGenome (database query 09/2021).
Unspecific drugs such as Tretinoin or Cabazitaxel were excluded (Supplementary
Table 1). Finally, 155 FDA/EMA-approved
drugs targeting cancer genetic alterations were included. These drug lists were
linked to 136 genes by querying databases of MD Anderson Cancer Center and Drugbank, which encode the potential sites
of binding and action (Supplementary Table 1). Moreover, special attention was
given to specific genetic alterations resulting in either drug sensitivity or
drug resistance of targeted therapy. Hereby the expert-crowdsourced,
publication-based databases from MyCancerGenome, CIViC, TARGET and OncoKB (Supplementary Table 2) were mined.